可商量
发表于 2025-3-25 04:13:31
http://reply.papertrans.cn/47/4624/462311/462311_21.png
安心地散步
发表于 2025-3-25 11:01:52
http://reply.papertrans.cn/47/4624/462311/462311_22.png
Stagger
发表于 2025-3-25 11:45:35
Dendritic Cells and class II pathways as well as the CD1 pathway and the significance of costimulation in the activation of T-cells are described. Role of DCs and the DC-secreted cytokines in induction of T-cell differentiation into different types of effector T-cells are discussed. The interaction between DCs and
西瓜
发表于 2025-3-25 18:21:15
http://reply.papertrans.cn/47/4624/462311/462311_24.png
rectocele
发表于 2025-3-25 21:55:32
http://reply.papertrans.cn/47/4624/462311/462311_25.png
让空气进入
发表于 2025-3-26 00:48:06
Interferon-α2bogy as well as pharmacology of IFN-α2b. The chapter begins with few historical details related to IFN discovery, then lists the different types of IFN families (Type I, II and III) and their respective receptors, describes the structure and SAR of IFN-α2b and discusses the details of IFNAR signal tr
Endearing
发表于 2025-3-26 07:44:42
http://reply.papertrans.cn/47/4624/462311/462311_27.png
cyanosis
发表于 2025-3-26 12:00:13
Ipilimumabt, the description of marketed ipilimumab formulation (Yervoy) is given along with the details of its clinical pharmacology. The mechanism of action of ipilimumab is then described followed by discussion on results from clinical trials that demonstrated the benefits of ipilimumab in treatment of pat
entitle
发表于 2025-3-26 16:25:26
Nivolumabcient mice (.. mice) are described. Next, the structure of PD-1 receptor, its biology and the signaling events that follow the activation of PD-1 receptor are explained. After giving a brief description of Opdivo, the marketed formulation of nivolumab, its clinical pharmacology and mechanism of acti
Adenocarcinoma
发表于 2025-3-26 19:50:43
http://reply.papertrans.cn/47/4624/462311/462311_30.png